It is concluded that the abdominally obese T2DM patients had a higher cluster of the components of the metabolic syndrome and are consequently at greater risk of cardiovascular disease (CVD). We recommend that diabetes education emphasizing the risk of CVD in patients with increased abdominal fat should be intensified in the developing countries.

IntroductionDemonstration of cardiovascular disease (CVD) markers in healthy subjects with normal blood chemistry tests underscores the need to study social determinants of risk factors to aid primary prevention worldwide; particularly in slums which harbor nearly 80% of rural to urban migrants in the epidemiologically transiting Africa where CVDs were previously unknown. The objective of this study was to assess lipids in relationship to alcohol consumption and BMI in a Nigerian slum.MethodsCross sectional community based prevalent study involving 191 apparently healthy inhabitants aged 18- 85 years recruited by convenient sampling. Heights, weights and BMIs were measured/ calculated, venous blood samples collected and lipid analysis done procedurally. Excel 13 and SPSS statistical soft ware were used for analysis and chart representation.ResultsTheir mean parameters were: Age (43.87 ± 1.62 years), triglycerides (TG; 1.20 ± 0.08mmol/L), total Cholesterol (TC; 4.54 ± 1.70mmol/L), low density lipoprotein cholesterol (LDLC; 3.69 ± 1.69mmol/L), high density lipoprotein cholesterol (HDLC; 0.61 ± 0.24mmol/L), RPI (7.12 ± 5.24), body mass index (BMI; 25.08 ± 5.18Kg/M2). TG and HDLC values were lowest in obese non alcohol drinkers while all other lipid parameters increased with BMI in both drinkers and non drinkers. Low HDLC prevalence was lowest in obese alcohol drinkers and highest (100%) in their non drinking counterparts. Having favourable HDLC was highest in daily alcohol consumers. No weekly drinker (0%) had favourable HDLC.ConclusionIgnorance, poor nutritional and health education may be major factors in the strategic challenge posed by the emergence of non communicable diseases in Africans.

Background: Despite the prevalence and quality of life impact of diabetic foot ulcer (DFU), novel topical and oral therapy standard-of-care remain an important research priority. To date, the lack of available data has made it difficult to assess the efficacy of topical and capsular RM diabetes wound cure for DFUs. Case Presentation: We report the case of a 59-year-old Nigerian woman P2+0 with 2 living children, a known diabetes mellitus patient since 2006 and has been compliant with her antidiabetic medications, who presented with complaint of right foot ulcer. We also report the case of a 69-year-old Nigerian man that presented with DFU. The latter is a known diabetic and hypertensive diagnosed 15 years prior to presentation. For the first case, both topical and capsular RM wound cure were applied twice daily over an area of the ulcer for 8 weeks. For the second case, only RM diabetes wound cure capsule applied twice daily was received for 8 weeks. Efficacy was analysed by lesion measurements and photographs to determine overall response rate (ORR), and complete response (CR). All doses were well tolerated, and potentially efficacious. At 8 weeks across all dose levels, subjects achieved 100.0% ORR and 50.0% CR. Conclusion: Application of topical and ingestion of the oral capsule of RM diabetes wound cure appear safe and well tolerated with some reduction in lesion pain. Some greater levels of lesion stabilization was observed in the subjects, and this demonstrated great clinical benefit in foot ulcers. A randomized, placebo-controlled trial to confirm these findings is recommended.